跳至主要内容
临床试验/PACTR202401802272880
PACTR202401802272880尚未招募3 期

H-PRIME: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden

Imperial College0 个研究点目标入组 1,800 人开始时间: 2023年8月6日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
1,800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
1 Month(s) 至 23 Month(s)(—)
性别
All

入选标准

  • ?Aged 1-10 years inclusive
  • ?Confirmed SCD (either by HPLC or IEF at a qualified laboratory)
  • ?Have received conjugate pneumococcal vaccination against Hib and S. pneumoniae (otherwise eligible but unvaccinated children will be vaccinated through the study as above)
  • ?Carer willing/able to provide consent and to bring the child for follow-up visits, as demonstrated by either regular attendance at SCD clinics to date, or attending two visits (one of which may be the screening visit) before randomisation

排除标准

  • ?Weighing <8kg – temporary exclusion pending the achievement of 8kg or more
  • ?Already meet criteria for starting hydroxyurea in national guidelines (frequent crises (>5/year), known abnormal transcranial Doppler ultrasound velocities, stroke or acute chest syndrome)
  • ?Already receiving hydroxyurea
  • ?Taking concomitant medications that are contraindicated with any of the trial medications (hydroxyurea, SP, DHA-PQP, penicillin V, cotrimoxazole) (including, but not limited to, nefazodone, verapamil, rifampicin, isoniazid, ethambutol)
  • ?A positive pregnancy test at screening or enrolment visits
  • ?Known cancer
  • ?A clinical history of previous or existing liver or renal diseases unrelated to sickle cell disease
  • ?Known cardiac ventricular dysfunction or failure or a previous history of cardiac arrhythmias
  • ?Known HIV (these children should receive cotrimoxazole prophylaxis and many will be receiving antiretrovirals that are contraindicated with one or more trial medications (zidovudine, amprenavir, atazanavir, indinavir, nelfinavir, ritonavir))
  • ?Current participation in any other clinical trial of an investigational medicinal product
  • ?Presence of acute infection on the day of screening (e.g. symptomatic P. falciparum malaria, pneumonia, septicaemia, meningitis, newly identified tuberculosis) – such children may be enrolled after recovery from an acute infection if they do not meet other exclusion criteria

研究者

发起方
Imperial College

相似试验

Hydroxyurea – Pragmatic Reduction in Mortality and... | 临床试验